TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing
Vancouver, British Columbia--(Newsfile Corp. - October 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests based on three-dimensional analysis of telomeres (which are the ends of chromosomes), today announced that it is advancing multiple clinical research initiatives to expand the comparative evaluation of its blood-based TELO-MRD assay against Adaptive Biotechnologies' clonoSEQ assay, a...